Jon Congleton - 19 Feb 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Executive Officer, Director
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
19 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 19:47:45 UTC
Previous filing
13 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Congleton Jon Chief Executive Officer, Director 150 N. RADNOR CHESTER RD., SUITE F200, RADNOR /s/ Adam Levy, Attorney-in-fact 20 Feb 2026 0001644975

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Award $0 +140,900 +22% $0.000000 780,051 19 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Award $0 +187,900 $0.000000 187,900 19 Feb 2026 Common Stock 187,900 $28.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.
F2 The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant